Published 02:50 IST, July 8th 2020
US grants $1.6 billion to Novavax for COVID-19 vaccine project under Operation Warp Speed
Novavax Inc. recently announced that it will be receiving $1.6 billion from the United States government for its COVID-19 vaccine programme.
Advertisement
vavax Inc. recently anunced that it will be receiving $1.6 billion from United States government for its COVID-19 vaccine programme. According to reports, funds will allow company to carry out vanced human trials of possible vaccine.
funding will also allow company to establish a manufacturing method that will make it possible for company to produce 100 million doses of possible COVID-19 vaccine as early as late 2020.
Advertisement
Biggest contribution under 'Operation Warp Speed'
Many pharmaceutical companies around world are embroiled in a race to develop COVID-19 vaccine. US President Donald Trump’s coronavirus vaccine programme has backed multiple companies like Johnson & Johnson and Merck & Co. but $1.6 billion funding grant to vavax Inc. has emerged as biggest contribution me to a single company under Operation Warp Speed.
Advertisement
As per vavax Inc.'s statement, funds will allow company to test a viable vaccine candidate by this fall. firm furr ded that it has around 30,000 subjects who have agreed to take part in trials. Earlier in May, vavax Inc also received $338 million from Coalition for Epidemic Preparedness Invations.
Advertisement
Chinese company in late-st trials
China’s leing provider of biopharmaceutical products, Sivac Biotech Ltd anunced on July 6 that it was entering phase III clinical trials sponsored by Instituto Butantan, Brazil, to test efficacy of its experimental COVID-19 vaccine.
As one of three pharmaceutical companies to reach late sts of trials, Sivac said it will recruit over 9,000 healthcare professionals to speed up process of developing potential cure for COVID-19, as per reports.
Advertisement
In collaboration with Butantan, a leing Brazilian producer of immubiological products and vaccines, Sivac has been given approval to run widescale trials by Brazilian National Regulatory ncy, Anvisa.
Advertisement
02:50 IST, July 8th 2020